The same is effective for five years, with effect from March 7, 2025.
The company said it is also producing TCCA at its Unit 11 in Khambhat, making it the only producer of TCCA products in India. The same will help it add ₹50 crore to ₹60 crore per annum in its total turnover from FY26, and will also help improve the bottom line of the company.
The company’s December quarter net profit gained 905.26% at ₹7.27 crore from ₹0.72 crore in the previous year. Its EBITDA was up 69.3% at ₹47.41 crore compared to the previous year’s ₹28.18 crore.
Bodal Chemicals shares ended the previous trade session 1.3% higher at ₹56.92 apiece. The stock has declined 17.72% this year, so far.
Also Read: Sun Pharma to acquire Checkpoint Therapeutics for $355 million in cash and milestone payments
